<DOC>
	<DOC>NCT02557074</DOC>
	<brief_summary>In a prospective pilot study the investigators showed that low doses of IL2 could be beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated. The objective of this study is to compare the long term efficacy of low doses of IL2 versus placebo in a multicenter prospective randomized double blind study.</brief_summary>
	<brief_title>TREg Activation in the Treatment of the PELADE (Alopecia Areata)</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Of more than 18 years old, Affiliated to the social security system, Clinical diagnosis of alopecia areata, 50 % of the surface of the scalp affected Last flaire started less than one year Alopecia areata resisting to at least 1 systematic treatment including phototherapy (UVB or PUVA), general corticosteroid therapy or methotrexate Signature of the informed consent Pregnancy or refusal of contraception at the women old enough to procreate, Refusal of contraception at the men Local treatment (dermocorticoïdes, minoxidil) or systematism (oral corticosteroid therapy, méthotrexate or the other immunosuppresseur) since less than 2 less, Evolutionary autoimmune cancer or disease or in forgiveness Excessive grip(taking) of alcohol (upper to 3 glasses of wine a day or one prelunch drink a day) Seropositivity VHC, VHB, or HIV Patient presenting a severe renal and/or hepatic insufficiency, Presenting patient one zoned, the chicken pox, the herpes, the tuberculosis, an evolutionary infectious disease, a respiratory failure … Vulnerable person (nobody under guardianship minor(miner), adults, deprived of freedom) IC in the treatment(processing) by IL2R Presenting a contraindication to ProleukinR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>